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In English
About seven years ago I wrote in this column about the role
and credibility of pharmacy operations.1 I maintained, for
example, that It seems that the pharmacies harbour plans for
increasing their buying power by new co-operation schemes
aimed at increasing their profit margins and enabling even
more visible campaigns directed at the buying public. The idea
that the pharmaceutical industry should compete with discounts
for the inclusion of their products in the merchandise of retail
pharmacies is outlining the position within the trade. 
At the end of the 1990’s there were no intimations of an
introduction of generic substitution. Nevertheless, the price
discount practices at the time caused concern to the extent
that negotiations were held between the National Agency for
Medicines, the Ministry of Social Affairs and Health and
various pharmaceutical entrepreneurs about the objectives of
pharmaceutical  advertising and standardised pricing of
medicinal products. The negotiations apparently did not
lead to a common commitment. In my editorial article at
the time I was only able to refer to the legal reforms which
would possibly have been necessary unless the issues were to
be resolved satisfactorily in some other way.  
A mention of the price discounts was nevertheless
included in the document Pharmaceutical Policy 2010 of the
Ministry of Social Affairs and Health.2 According to the
document, any discounts that are to be implemented will
benefit the whole population, and the discounts should be
available at a standardised rate to all pharmacies and thereby
also to their customers. 
The generic substitution in 2003 resulted in the discount
practices used by the pharmaceutical industry and pharma-
cies also being applied to prescription-only-medicines. The
situation blew up into an unprecedented media storm in the
spring of 2005. In its review to the Ministry of Social Affairs
and Health, the National Agency for Medicines maintained
that the Medicines’ Act had not been violated. The central
role played by the pharmacies in the successful introduction
of generic substitution has not been denied. The public
image of pharmacies had nevertheless suffered a considerable
blow.
The legislator has now given his verdict. According to
the Medicines’ Act reform, the wholesale price of medicines
must be universal to all pharmacies and their subsidiaries.
The wholesale price must take account of all deductions,
rebates and other benefits granted to pharmacies and their
subsidiaries.
The government argued for its proposal (HE 107/2005)
by stating for example as follows: The prohibition of discounts
to individual pharmacies improves the efficiency of drug distrib-
ution based on health aspects, because the sale of medicines by
pharmacies will then, to an increasing degree, consider the needs
of the customers in protecting their health. In its report, the
Constitutional Committee of the Parliament stated (PeVL
56/2005) as follows: The regulation fulfils for its part the
responsibility prescribed by law, Section 19, Subsection 3 of the
Constitution, for the official authority to promote the health of
the population.
It should now be clear to all parties in the pharmaceuti-
cal sector that the most important merit of the Finnish phar-
macy system in operating as it does,  under special regul-
ations, is associated with a  pharmaceutical distribution
which is based on aspects of health. The responsibilities are
stipulated in the Medicines’ Act. The State is responsible for
the financial framework of the system. The principles are
equal for all pharmacies, whether they are large or small, or
part of any retail chains or not, and whether their owners are
independent pharmacists or universities.
1  TABU 1/1999, p. 4.
2 Pharmaceutical Policy 2010. Ministry of Social Affairs and Health
2003:11
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Epidemic nephropathy
Each hantavirus lives in nature in its
own host rodent. Finnish researchers
detected in 1980 that epidemic
nephropathy is caused by a virus
(Clethrionomys glareolus) found in bank
voles, and the virus was named in
accordance with the location where it
was found. Humans can contract
Puumala virus through bank vole
droppings, apparently via the airways.
Epidemic nephropathy has not been
found to be transmissible from human
to human.
About 1,000 serologically
confirmed cases of Puumala virus
infection are found in Finland every
year. The seroprevalence of the virus in
the population is about 5% (even 11%
in eastern Finland), and the frequency
of serologically confirmed cases of epi-
demic nephropathy is 19 per 100,000.
It can consequently be deduced that
the number of serologically undiag-
nosed cases is about six times higher
than those diagnosed. A number of the
diagnoses of epidemic nephropathy are
evidently made on the basis of the typ-
ical clinical picture without being sero-
logically confirmed, but a high propor-
tion of the cases probably remain un-
diagnosed due to the lack or insignifi-
cance of symptoms. The highest preva-
lence of the disease is found in eastern
and central Finland with the majority
of the cases occurring between August
and January. Two thirds of those con-
tracting the disease are men. Animal
researchers, forest workers and farmers
are some of the risk groups. The
disease is rarer and milder in form in
children compared to adults.
The pathogenesis of epidemic
nephropathy still remains mostly
unsolved. The characteristics of all
hantavirus diseases include increased
capillary permeability, and it is conse-
quently suggested that the target of the
virus would be an endothelial cell.
Hantaviruses do not, however, cause
cell destruction, and it is presumed
that cytotoxic T cells with immunolog-
ical mechanism play a part in the
pathogenesis.
Clinical picture
The most common symptoms and
findings of epidemic nephropathy can
be found in Tables 1 and 2.
The incubation period of epidemic
nephropathy is between 2 and 4 weeks.
The clinical picture is very varied. The
majority of people infected with
Puumala virus exhibit symptoms
which are quite mild, but in some
individuals the disease may be severe
to the extent that intensive care is
required. It has been found that the
host’s immune response plays a part in
the course of the disease. The alleles
HLA-B8 and HLA-DRB1*0301
(DR3) of the human leukocyte antigen
system have been found to be associat-
ed with severe epidemic nephropathy.
Hypotension occurring in the initial
stages of the disease and severe renal
failure are particularly associated with
this tissue type.  
The most common symptoms
include rapidly rising high fever,
headache, nausea, vomiting, and
abdominal and back pain. The pain
may be so severe that meningitis or
appendicitis, for instance, may be sus-
pected at first. Hypotension or even a
shock may occur in the initial stages of
the disease. About a third of the
patients experience visual disturbances,
whereas the transient short-sightedness
characteristic of epidemic nephropathy
only occurs in a small number of
patients. The onset of obscured vision
is rapid and associated with the fever
stage. The vision is restored to normal
within a few days.
A few days after the onset of fever
the urinary volumes are reduced, and a
transient, acute renal insufficiency of
varying severity occurs. In fact, the
condition may be associated with a
severe fluid retention, even pulmonary
oedema. A great increase in the urinary
volume occurs in the stage of recovery.
Polyuria may occasionally be found
without the preceding oliguria, which
is an indication of a disturbance of
renotubular function.
Despite the fact that it is a question
of a haemorrhagic fever, with throm-
bocytopaenia being a common finding,
haemorrhages are rare. Transient con-
junctival sugillation, epistaxis, macro-
scopic haematuria, dermal or mucosal
petechiae and bleeding at the site of
injection may occur. Gastrointestinal
haemorrhage is also a possibility.
Epidemic nephropathy is a gener-
alised infection, and the symptoms and
findings in a patient may occasionally
be atypical. Rare phenomena have
Epidemic nephropathy is an acute infection caused by Puumala virus of the hantaviruses group. Hantaviruses are enveloped
RNA viruses and are found everywhere in the world. Haemorrhagic fever with renal syndrome is caused by Dobrava, Saare-
maa and Puumala viruses in Europe and Hantaan and Seoul viruses in Asia. Hantavirus pulmonary syndrome is found on
the American continent and is caused by, for example, Sin Nombre and Andes viruses. 
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been reported in the disease, such as
perimyocarditis, meningoencephalitis,
hepatitis, acute disseminated ence-
phalomyelitis and Guillain-Barré syn-
drome. 
The prognosis of epidemic
nephropathy is considered to be good.
The patients usually make a total
recovery, but tiredness, for example,
may continue for several weeks after
the acute stage. Rare long-term adverse
effects following epidemic nephropa-
thy have been described, e.g.
panhypopituitarism and chronic
glomerulonephritis. The mortality rate
is highly insignificant (0.1%). Dissem-
inated intravascular coagulation
syndrome (DIC), haemorrhage into
and necrosis of the hypophysis, and
haemorrhage in other organs, have also
been described in association with
death. The mechanism of death may
also be shock or pulmonary oedema.
Laboratory and X-ray findings 
The typical laboratory findings in a
patient suffering from epidemic
nephropathy include protein-uria,
microscopic haematuria, thrombocy-
topaenia, leucocytosis, elevated plasma
creatinine, C-reactive protein (CRP)
and liver enzyme concentrations, and
hypoalbuminaemia (Table 2). In the
initial stages of the disease, as a sign of
haemoconcentration, high haemato-
crite levels may occur, but as the dis-
ease progresses transient anaemia often
develops. Electrolyte disturbances are
common, but their clinical importance
is usually minor.
A third of the hospitalised adult
patients are found to have changes in
the lung X-ray: pleural fluid, shadows
in the pulmonary parenchyma and,
albeit seldom, pulmonary oedema. The
changes have been found to be linked
with the compli-cations of renal insuf-
ficiency and fluid retention.
Ultrasound examinations show
enlarged kidneys, and pleural, pericar-
dial or perirenal fluid accumulation.
An electrocardiogram also shows tran-
sient abnormal findings, such as T
inversions and ST segment changes.
Diagnosis 
The diagnosis of epidemic nephropa-
thy is based on the clinical picture and
serology. The diagnosis is made on one
serum sample by using immunofluo-
rescence and/or enzyme immunologi-
cal techniques. Already at the initial
stages of epidemic nephropathy, and
on the 6th day of illness at the latest,
most patients are found to have anti-
bodies of class IgM and usually also of
IgG against the Puumala virus. Nega-
tive IgG and IgM results exclude epi-
demic nephropathy. A positive IgG
result and a negative IgM result are an
indication of a previous epidemic
nephropathy.  
Lifelong immunity follows a han-
tavirus infection. A recurrence of epi-
demic nephropathy has never been
seen. A differential diagnosis should
take into account any infection (espe-
cially sepsis) caused by other viruses
and bacteria and other conditions
causing acute renal failure as well.
Treatment 
The treatment of epidemic nephropa-
thy is symptomatic, consisting essen-
tially of treatment of pain and control
of the fluid balance. Fluid therapy
requires precise individual adjustment.
On arrival at hospital the patient may
suffer from hypotension and hypovol-
aemia, but careless administration of
fluid may quickly result in pulmonary
oedema, especially if the patient suffers
from oliguric renal insufficiency at the
same time. About 5% of hospitalised
patients need to undergo dialysis. Pain-
relieving medication is also required.
Paracetamol is an appropriate
analgesic, but anti-inflammatory anal-
gesics should be avoided since they
impair renal function. 
Mild cases can be treated in out-
patient care facilities. On suspicion of
epidemic nephropathy it is nevertheless
recommended that the patient is sent
for hospital treatment. Hospitalisation
at least is required if the patient's gen-
eral condition is poor, if the patient
evidently suffers from dehydration,
fluid retention, oliguria, or renal insuf-
ficiency, or if the diagnosis cannot be
confirmed.
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Table 1. Symptoms of epidemic nephropathy
Symptom Frequency (%)
Fever 98–100
Headache 62–90
Back pain 54–82
Abdominal pain 43–67
Nausea/vomiting 58–84
Myalgia 27–69
Oliguria (<400 ml/day) 54–70
Polyuria (>2000 ml/day) 97
Visual disturbances 12–36
Diarrhoea 12–20 
Cough 6–32
Table 2.  Laboratory findings in epidemic nephropathy
Finding Prevalence (%)
Leucocytosis  >10.0 x109/l 23–57
Thrombocytopaenia 75
Proteinuria 94–100
Haematuria 58–87
Elevated creatinine 86–96
Elevated CRP 52–60
Elevated liver enzymes 41–60
Hypoalbuminaemia/hypoproteinaemia 24–64
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Milk allergy is one of the most
common food allergies, affecting about
three per cent of infants. In the major-
ity of patients the symptoms will have
disappeared by school age. Hypersensi-
tivity to milk also occurs in a small
proportion of the adult population. It
is exhibited in the form of skin symp-
toms (atopic rash or, less frequently,
urticaria), intestinal symptoms (eructa-
tion or vomiting, diarrhoea and chil-
dren’s colic), airways symptoms (rhini-
tis, cough) and, in exceptional cases,
even anaphylactic reaction. Milk aller-
gy is often also associated with other
allergies. Atopic tendency also increas-
es the likelihood of asthma.
A common excipient in the powder
inhalers used in the treatment of asth-
ma is lactose which may even after
purification contain small concentra-
tions of milk protein. The following is
a description of a young patient of
mine with symptoms of milk allergy
developing on the introduction of
treatment with a powder inhaler con-
taining lactose as one of the excipients. 
My 5-year-old patient was
diagnosed with a multiple food allergy
and an allergy to cow’s milk protein
with potent symptoms.  The patients
also suffered from allergic rhinitis and
asthma. The asthma had previously
been treated with Flixotide Evohaler
which was replaced by a powder
inhaler, a common practice in paedi-
atric asthma patients of this age. The
patient developed urticaria and dysp-
noea soon after the introduction of
Flixotide diskus inhalation powder.
Dyspnoea was relieved by Buventol
Easyhaler administered by the parents.
The parents’ first suspicion was that
the urticaria would be a result of a
dietary error until after a couple of
weeks of reflection they finally spotted
a mention in the Flixotide diskus SPC
about the milk protein that the pow-
der contained. The symptoms were
alleviated when the patient’s previous
medication was reinstated (Buventol
was also withdrawn and replaced by
Ventoline Evohaler). The urticaria and
dyspnoea were reversible thereafter.
In addition to the reaction above,
the Finnish Adverse Drug Reaction
database of the National Agency for
Medicines has received reports of two
other children who developed
symptoms of hypersensitivity while
using inhalation powders containing
lactose. 
One of these reports mentioned
milk allergy. A 13-year-old girl, who in
addition to citrus fruit and fish allergy
also suffered from milk allergy, devel-
oped a laryngeal oedema in association
with the administration of Seretide
diskus. 
The other one concerned an 8-
year-old girl who developed a rash in
association with the use of Serevent
diskus when the dose was 50 microg x
4 (no rash developed at the dosage rate
of 50 microg x 2 per day).
The SPC and PIL of Flixotide
diskus, under the section List of excipi-
ents’ includes a mention of the fact that
the product contains lactose monohy-
drate as one of its excipients. Under
the same section there is a mention in
brackets that the excipient contains
milk protein.
Thomas Rintala ADR News
Paeditrician
Iisalmi Hospital
My own observation of an adverse drug reaction
Milk protein of an anti-asthmatic is the cause of
exacerbation of milk allergy symptoms
In English
In 2004 there were about 220,000 dia-
betics (over 4% of the population) in
Finland, 31,000 of whom suffered
from type 1 diabetes and the rest from
type 2 diabetes [1]. A total of 161,305
diabetics in the country were entitled
to a special refund of their drug
expenses [2]. 
In 2004, the prevalence of type 1
or juvenile-onset diabetes in Finland
was the highest in the world [3].
Infantile diabetes is usually of type 1,
but type 2 is constantly on the increase
even in young patients. At the end of
2004, a total of 3,478 children under
the age of 15 were entitled to a special
refund of their antidiabetic drug
expenditure [4]. 
Type 1 diabetes is usually treated
with insulin [5]. The most important
recent changes in the pharmaceutical
care of diabetes include fast-acting
insulins (lispro and aspart,
A10AB04/05), long-acting insulin
glargine (A10AE04), and the insulin
pump, which is programmed to
administer either a short-acting human
insulin (A10AB01) or a fast-acting
insulin as a continuous subcutaneous
infusion [6-10]. The biggest benefits of
these most recent therapies, especially
in the treatment of diabetic children,
consist of a reduced frequency of
hypoglycaemia and an improvement in
the quality of life [6, 9]. As a form of
therapy, both the basic insulin–meal-
time insulin and insulin pump therapy
are highly appropriate especially in the
treatment of diabetic children [8]. In
2003 there were 764 insulin pump
users in Finland, 207 of whom were
children [11]. 
A survey has been carried out with
the object of establishing the drugs
that were used in 2004 in the treat-
ment of diabetes in children under the
age of 15 and determining the distrib-
ution of the use and costs of insulin
therapies in the country by district,
age, gender and mother tongue.
The survey was carried out as a reg-
ister-based survey. The ATC group of
short-acting insulins and analogues was
divided into short-acting human
insulins (A10AB01) and fast-acting
insulins (A10AB04 and A10AB05) in
the analysis. 
Medicines 
The survey material covered 1,460 dia-
betic children under the age of 15
(42% of those with entitlement to spe-
cial refunds at the end of 2004). Judg-
ing from the survey material, diabetes
is slightly more common in boys, in
children with Finnish mother tongue,
and in children living in small or
medium sized municipalities, in com-
parison with girls, children with a
mother tongue other than Finnish or
Swedish, and children living in large
municipalities.
Insulin was used in all the children
in the survey except for two 10–14-
year-olds, who were receiving oral
blood glucose-reducing drugs
(metformin), i.e. they are likely to suf-
fer from type 2 diabetes. Five of the
most common diabetic therapies in
children under the age of 15 are shown
by age groups in Table. They display
the drug therapies of 1,140 children
(78% of the survey material). The chil-
dren were usually treated with a short-
acting human insulin and/or a fast-act-
ing insulin and a long-acting insulin
and/or insulin glargine (1,079
children), i.e. a fairly typical basic
insulin–mealtime insulin therapy. The
differences in medications between the
age groups were minor, but the drug
combinations were usually the same in
all the age groups (Table). The drug
therapies did not differ significantly
between the genders. An appraisal by
age group showed a small difference in
that 0–4-year-old girls were treated
with insulin glargine slightly more
often than boys of the same age.
The most common single drug
therapy used was a combination of a
short-acting human insulin and a fast-
acting insulin. According to the
records, 379 children (26%) of the
total number had administered to
them either a fast-acting insulin (55
children) or a combination of a short-
acting human insulin and a fast-acting
insulin (324 children) as the only drug
therapy.  It is likely that these patients
had been receiving concomitant thera-
py with an NPH insulin or a long-act-
ing analogue in accordance with nor-
mal therapeutic practice. Insulin
detemir, for example, was introduced
on to the market in August and was
placed in the basic refund category at
the beginning of December 2004, i.e.
its use will not show up in the records
of the Social Insurance Institution
before December. The drug consump-
tion statistics of NAM show, however,
that insulin detemir has been sold by
pharmacies to the value of about EUR
36,000 in 2004. It was sold with the
purpose of compassionate use in the
treatment of two children and eight
adults only during the same year. The
prices of all NPH insulins and insulin
glargine exceeded the deductible of
EUR 5 per purchase, i.e. they have not
been excluded from the data because
of their affordability. It remains
unclear, therefore, where these patients
have obtained their insulin from in
2004.
It is not possible to distinguish
insulin pump users in the patient data,
because, in addition to the fast-acting
insulin used in the pump they should
usually also have some sort of system
in place to cover for the duration of
maintenance or breakage of the pump.
Consequently, they should presumably
yearly make at least some purchases of
a long-acting analogue or an NPH
insulin.
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The use of antidiabetic agents in children in 2004 
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Costs
The average annual costs of antidiabet-
ic agents for children totalled EUR
626 (n=1,460 with a median of EUR
556). The drug costs relative to girls
were higher than those relative to boys
of the same age.
The main attention in the costs of
antidiabetic agents for children was
drawn to the use of insulin glargine
due to its relatively high price. The
total annual drug costs accumulated by
children receiving insulin glargine
averaged EUR 843, whereas the costs
of the other insulin therapies for chil-
dren significantly lower, averaging in
EUR 521 (p=0.00).
Nearly all antidiabetic agents were
included in the higher special refund
category of 100% in the year 2004;
the patients themselves only paid a
fixed deductible of EUR 5 per
purchase. The true refund percentage
in the entire data after deductibles was
96.4.
Conclusions 
The survey analysed the diabetic drug
treatment and costs of 1,460 children
under the age of 15 in the year 2004.
The data showed that they were using
a) a fast-acting insulin and/or a short-
acting insulin and a long-acting NPH
insulin and/or insulin glargine (1,079
children) or b) a fast-acting insulin
alone or a combination of a fast-acting
and a short-acting human insulin (379
children). Two children were using oral
blood glucose reducing drugs.
The average annual drug costs rela-
tive to children amounted to EUR
626. The costs accumulated by girls
were slightly higher than those by
boys, and they increased with age for
both groups. The annual drug costs of
insulin glargine users were the highest
of all.
The differences in medication
between the genders were insignificant,
but there were significant regional dif-
ferences in the use of insulin glargine.  
See additional figures on pages 35–38.
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Translation Mervi Moisander
Age Pos. Drug therapies Number   % Median cost 
of users EUR/person
0–4 y 
1 Short-acting human insulins (A10AB01) + long-acting insulins (A10AC01) 31 34 231,6
2 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05) 19 21 278,5
3 Fast-acting insulins (A10AB04/05) + long-acting insulins (A10AC01) 11 12 263,1
4 Fast-acting insulins (A10AB04/05) + insulin glargine (A10AE04) 10 11 385,7
5 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05) +
+ long-acting insulins (A10AC01) 7 8 218,2
5–9 y 
1 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05) 165 34 378,9
2 Short-acting human insulins (A10AB01) + long-acting insulins (A10AC01) 97 20 308,0
3 Fast-acting insulins (A10AB04/05) + insulin glargine (A10AE04) 48 10 533,2
4 Fast-acting insulins (A10AB04/05) + long-acting insulins (A10AC01) 46 10 373,0
5 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05)  
+ long-acting insulins (A10AC01) 37 8 514,7
10–14 y 
1 Fast-acting insulins (A10AB04/05) + insulin glargine (A10AE04) 255 29 879,0
2 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05) 139 16 576,0
3 Short-acting human insulins (A10AB01) + fast-acting insulins (A10AB04/05)
+ long-acting insulins (A10AC01) 107 12 800,5
4 Fast-acting insulins (A10AB04/05) + long-acting insulins (A10AC01) 87 10 621,5
5 Fast-acting insulins (A10AB04/05) + long-acting insulins (A10AC01) +
+ insulin glargine (A10AE04) 81 9 872,8
Five of the most commonly used antidiabetic drugs by age groups
